CYTK
Price
$40.05
Change
+$2.06 (+5.42%)
Updated
Apr 24, 02:20 PM (EDT)
Capitalization
4.51B
7 days until earnings call
KRYS
Price
$166.57
Change
+$0.77 (+0.46%)
Updated
Apr 24, 02:34 PM (EDT)
Capitalization
4.88B
12 days until earnings call
Ad is loading...

CYTK vs KRYS

Header iconCYTK vs KRYS Comparison
Open Charts CYTK vs KRYSBanner chart's image
Cytokinetics
Price$40.05
Change+$2.06 (+5.42%)
Volume$200
Capitalization4.51B
Krystal Biotech
Price$166.57
Change+$0.77 (+0.46%)
Volume$100
Capitalization4.88B
CYTK vs KRYS Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. KRYS commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Hold and KRYS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CYTK: $38.00 vs. KRYS: $165.80)
Brand notoriety: CYTK and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 59% vs. KRYS: 73%
Market capitalization -- CYTK: $4.51B vs. KRYS: $4.88B
CYTK [@Biotechnology] is valued at $4.51B. KRYS’s [@Biotechnology] market capitalization is $4.88B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 6 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • KRYS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -2.94% price change this week, while KRYS (@Biotechnology) price change was +0.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.88B) has a higher market cap than CYTK($4.51B). KRYS YTD gains are higher at: 5.834 vs. CYTK (-19.218). KRYS has higher annual earnings (EBITDA): 110M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. KRYS (598M). KRYS has less debt than CYTK: KRYS (7.26M) vs CYTK (789M). KRYS has higher revenues than CYTK: KRYS (291M) vs CYTK (18.5M).
CYTKKRYSCYTK / KRYS
Capitalization4.51B4.88B92%
EBITDA-493.48M110M-449%
Gain YTD-19.2185.834-329%
P/E RatioN/A56.27-
Revenue18.5M291M6%
Total Cash1.08B598M180%
Total Debt789M7.26M10,866%
FUNDAMENTALS RATINGS
CYTK vs KRYS: Fundamental Ratings
CYTK
KRYS
OUTLOOK RATING
1..100
186
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
6718
SMR RATING
1..100
9967
PRICE GROWTH RATING
1..100
8554
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as CYTK (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CYTK’s over the last 12 months.

KRYS's Profit vs Risk Rating (18) in the Pharmaceuticals Major industry is somewhat better than the same rating for CYTK (67) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than CYTK’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as CYTK (99) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CYTK’s over the last 12 months.

KRYS's Price Growth Rating (54) in the Pharmaceuticals Major industry is in the same range as CYTK (85) in the Biotechnology industry. This means that KRYS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for KRYS (100) in the Pharmaceuticals Major industry. This means that CYTK’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKKRYS
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 10 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 17 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JPSE41.190.52
+1.28%
JPMorgan Divers Ret US Small Cap Eq ETF
WTMF33.980.31
+0.92%
WisdomTree Managed Futures Strategy ETF
FFIU21.560.06
+0.30%
Fieldstone UVA Uncons Md-Trm Fxd Inc ETF
REGL78.320.21
+0.28%
ProShares S&P MidCap 400 Dividend Arst
HAPY20.89N/A
N/A
Harbor Human Capital Factor Uncons ETF

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+0.50%
IDYA - CYTK
48%
Loosely correlated
+0.91%
ACLX - CYTK
46%
Loosely correlated
+0.81%
KRYS - CYTK
46%
Loosely correlated
-1.78%
TRDA - CYTK
43%
Loosely correlated
N/A
DNLI - CYTK
43%
Loosely correlated
+1.85%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-1.78%
ACLX - KRYS
55%
Loosely correlated
+0.81%
IDYA - KRYS
51%
Loosely correlated
+0.91%
CRNX - KRYS
50%
Loosely correlated
+3.55%
CGON - KRYS
49%
Loosely correlated
+1.22%
ROIV - KRYS
48%
Loosely correlated
+2.98%
More